Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of recombinant EGF-CRM197 therapeutic cancer vaccine plus chemotherapy in previously treated non-small cell lung cancer
CTR20210202Phase 2Active
- Sponsor
- Huidun Biotech
- Start
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of EGF-CRM197 in non-small cell lung cancer (NSCLC), sponsored by Huidun Biotech. Started Dec 2021; status: active.
02
Drugs
EGF-CRM197
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210202.